Ribomic Inc. (4591.T)

JPY 80.0

(0.0%)

Market Cap (In JPY)

3.3 Billion

Revenue (In JPY)

-

Net Income (In JPY)

-1.02 Billion

Avg. Volume

2.5 Million

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
60.0-123.0
PE
-
EPS
-
Beta Value
0.602
ISIN
JP3974850004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yoshikazu Nakamura Ph.D.
Employee Count
-
Website
https://www.ribomic.com
Ipo Date
2014-09-25
Details
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.